Advanced search
Publication Cover
Cutaneous and Ocular Toxicology Volume 36, 2017 - Issue 1
Submit an article Journal homepage
367
Views
7
CrossRef citations to date
0
Altmetric
Research Article

The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema

Huseyin GuzelDepartment of Ophthalmology, Tatvan State Hospital, Bitlis, Turkey, Correspondence[email protected]
,
Berker BakbakDepartment of Ophthalmology, Selcuk University, Konya, Turkey, and
,
Mehmet Talay KoyluDepartment of Ophthalmology, Tatvan Military Hospital, Bitlis, Turkey
,
Saban GonulDepartment of Ophthalmology, Selcuk University, Konya, Turkey, and
,
Banu OzturkDepartment of Ophthalmology, Selcuk University, Konya, Turkey, and
&
Sansal GedikDepartment of Ophthalmology, Selcuk University, Konya, Turkey, and
Pages 5-8 | Received 08 Aug 2015, Accepted 06 Jan 2016, Published online: 24 Feb 2016

References

  • Kim EK, Kang SW, Kim JY, et al. Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts. Invest Ophthalmol Vis Sci 2013;54:3922–3931.
  • Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29:875–912.
  • Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013;4:19–26.
  • Chiang C-C, Chen W-L, Lin J-M, Tsai Y-Y. Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol 2008;146:688–691.
  • Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, et al. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea 2010;29:849–852.
  • Campbell RJ, Bell CM, de LP, et al. Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Curr Opin Ophthalmol 2013;24:197–204.
  • Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557–563.
  • Shalam KV, Agarwal S, Brar VS, et al. Evaluation of cytotoxic effects of bevacizumab on human corneal cells. Cornea 2009;28:328–333.
  • Türkcü FM, Cinar Y, Türkcü G, et al. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model. Cutan Ocul Toxicol 2014;33:138–144.
  • Keating AM, Jacobs DS. Anti-VEGF treatment of corneal neovascularization. Ocul Surf 2011;9:227–238.
  • Sawada O, Kawamura H, Kakinoki M, et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125:1363–6
  • Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmol 2007;114:855–859.
  • Shin JP, Lee JW, Sohn BJ, et al. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation. J Glaucoma 2009;18:589–594.
  • Tae-im Kim JLC, Hong JP, Min K, et al. Bevacizumab application delays epithelial healing in rabbit cornea. Investig Ophthalmol Visual Sci 2009;50:4653–4659.
  • Rusovici R, Sakhalkar M, Chalam KV. Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells. Mol Vis 2011;17:3339–3346.
  • Kernt M, Welge-Lüssen U, Yu A, et al. [Bevacizumab is not toxic to human anterior-and posterior-segment cultured cells]. Ophthalmologe 2007;104:965–971.
  • Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977–982.
  • Hosny MH, Zayed MA, Shalaby AM, Eissa IM. Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther 2009;25:513–518.
  • Lichtinger A, Yeung SN, Kim P, et al. Corneal endothelial safety following subconjunctival and intrastromal injection of bevacizumab for corneal neovascularization. Int Ophthalmol 2014;34:597–601.
  • Horozoğlu F, Gönen T, Yaşar M, et al. Comparison of corneal endothelial changes after a single-dose injection of bevacizumab or ranibizumab. Turk J Ophthalmol 2013;43:391–394.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.